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Background: Hereditary Angioedema (HAE) is a rare autosomal dominant condition characterized by episodic
angioedema, which may be triggered by invasive procedures and surgery. C1 inhibitor (C1 INH) was approved in
the United States and Canada in 2009 and 2010, respectively, for the treatment of acute attacks. Most recently in
April 2013, it was approved in Europe for short-term prophylaxis (STP), prior to medical, dental, or surgical
procedures, to prevent HAE attacks in both children and adults. Currently, C1 INH is not approved in Canada or the
United States for STP of HAE attacks. Our objective was to demonstrate the effectiveness of C1 INH as a short-term
prophylactic treatment for patients with Type I HAE undergoing invasive surgical procedures.
Methods: A retrospective chart review between 1997-2013 was performed at one Canadian Tertiary Care Allergy
and Asthma Clinic affiliated with The Ottawa Hospital, in Ottawa, Canada. The standard dose of C1 INH for STP was
10 or 20 U/kg.
Results: In all 24 procedures, there were no post-procedure HAE attacks after short-term prophylactic administration
of C1 INH.
Conclusions: In this retrospective chart review at one tertiary care Allergy and Clinical Immunology Clinic,
short-term prophylactic use of C1 INH was found to be effective at preventing post-procedure HAE attacks, in
patients diagnosed with Type I HAE.
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Hereditary Angioedema (HAE) is a rare autosomal
dominant disease with a prevalence of approximately 1
in 50,000 [1]. There are 3 variants of HAE, which
present with episodic attacks of non-pitting and non-
pruritic edema; however, they may be differentiated by
CI INH level and function. Type I affects 85% of
patients and is distinguished by low plasma levels of
C1 INH; while in Type II, which affects 15% of pa-
tients, inactive C1 INH is produced, but plasma levels
are normal. Type III is rare, primarily affects females,* Correspondence: genevieve.gavigan@gmail.com
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unless otherwise stated.and is characterized by normal C1 INH level and function;
it may be estrogen dependent [1].
Significant mortality is associated with HAE; undiag-
nosed HAE carries a 30-40% mortality rate, mainly from
upper airway obstruction [2]. Furthermore, patients suf-
fer from important morbidity and disabling symptoms,
and may be debilitated for 20-100 days per year [3]. New
medications have been developed for both treatment of
acute attacks and for prophylaxis (short-term and long-
term). Short-term prophylaxis (STP) is used to prevent
attacks surrounding known triggers (surgeries, invasive
dental procedures, stressful life events), while long-term
prophylaxis is reserved for patients who suffer from
frequent HAE attacks.
The World Allergy Organization (WAO) recognizes that
physical and emotional stress associated with surgery may
elicit HAE attacks. These attacks usually occur 4-30 hoursl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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trauma, suggesting that dental surgery may be associated
with significant risk because of potential airway edema [4].
C1 INH has been marketed for the treatment of HAE
attacks in Europe for over 30 years; it was officially ap-
proved in Europe for acute HAE attacks in 2008. It was
approved in the United States (US) and Canada, in 2009
and 2010, respectively, for the treatment of moderate to
severe acute abdominal and facial attacks. In April 2013,
C1 INH was approved in Europe for STP in children and
adults, prior to medical, dental, or surgical procedures. It
is not currently approved for STP in Canada or the US.
Our objective is to demonstrate the effectiveness of C1
INH as a short-term prophylactic treatment for patients
with Type I HAE undergoing surgical procedures.
Methods
A retrospective chart review was performed at one
Canadian Tertiary Care Allergy and Clinical Immunology
Clinic (Yang Medicine), affiliated with The Ottawa
Hospital in Ottawa, Canada. The study included all pa-
tients with type I HAE who had received short-term
prophylactic treatment with C1 INH (Berinert®) prior
to an invasive procedure, surgery, dental work, or child
birth, between 1997-2013. The diagnosis of Type I HAE
was established in these patients based on clinical history,
family history, and laboratory values (C4 level, C1 INH
level). The primary outcome was the number of post-
procedural HAE attacks after short-term prophylactic
administration of C1 INH.
The standard dose for C1 INH (Berinert®) was either
10 U/kg or 20 U/kg. This range in dosing can be explained
by to the long duration of the study (1997-2013). Prior to
the IMPACT-1 trial in 2009, the dose of 10 U/kg was used
as standard; however after the IMPACT-1 trial found that
20 U/kg was superior to 10 U/kg [5], this dose was utilized
instead.
Prior to 2010 (when Berinert® was approved in Canada
for acute attacks), the medication was only accessible
through Health Canada’s Special Access Programme on
a case-by-case basis. It was requested for each HAE pa-
tient on the basis of the possible serious and potential
life-threatening nature of an HAE episode caused by an
invasive procedure or surgery.
Results
At total of 24 surgical procedures (Table 1) were per-
formed on 12 patients (4 male, 8 female) with Type I
HAE. The average number of procedures per patient
was 2 (range 1-6), and the average age at the time of the
procedure was 42 (range 19-62).
The majority of surgical procedures (22/24) were treated
with a short-term prophylactic C1 INH dose of 1000 U,
1500 U, or 2000 U, which corresponded to a dose of 10 or20 U/kg, administered IV over a 20-30 minute period just
before the procedure. Procedure 4 was treated with an in-
fusion of C1 INH, resulting in a higher cumulative dose.
This decision was based on mutiple factors, including the
invasiveness of the surgery, the need for intubation, the
patient’s history of a possible previous laryngeal attack,
and the patient being off his Danazol at the time of the
surgery. Procedure 20 also received a higher prophylactic
dose of C1 INH (3000 U), because of the seriousness and
length of the surgery.
In eight of the procedures, the patient received STP
with C1 INH in addition to long-term treatment with
Danazol. STP with C1 INH was provided to these patients
as they continued to experience HAE attacks while taking
Danazol.
In all 24 surgical procedures, there were no post-
procedure HAE attacks after short-term prophylactic ad-
ministration of C1 INH. Furthermore, no patient required
additional dosing because of concern regarding prodromal
symptoms of an impending HAE attack.
Discussion
In our experience, C1 INH was an effective short-term
prophylactic treatment for Type I HAE patients undergo-
ing invasive procedures. There were no post-procedural
HAE attacks following any of the 24 procedures. Our re-
sults are consistent with a previous report by Grant et al,
where pre-procedural nanofiltered C1 INH (Cinryze®) was
used to prevent HAE attacks. In that study, 41 patients
(33 adults, 8 children) received C1 INH prior to 91 proce-
dures (87/91 procedures were treated with a dose of 1000
U for STP). No HAE attack followed 89 of 91 procedures;
the 2 attacks were successfully treated with 1000 U of C1
INH [6]. It is noteworthy, however, that the majority of
the procedures in the study by Grant et al did not require
pretreatment.
Surgery is a recognized precipitant of HAE attacks [4].
Bork et al. observed 124 attacks (88 facial, 8 laryngeal,
28 combined) following 577 dental extractions without
prophylaxis [7]. Even with STP, HAE attacks are not
completely eliminated. Farkas et al. reported 13 HAE at-
tacks following 134 surgical procedures despite prophy-
laxis: 5/38 with Danazol, 3/9 with Tranexamic acid, and
5/87 with 500 U of C1 INH (Berinert®) [8]. Different
short-term prophylactic doses of C1 INH (Berinert®)
were assessed for dental extraction; 12 attacks followed
75 extractions after 500 U, and 4 attacks followed 53
extractions despite 1000 U [7].
While the studies by Grant et al, Bork et al, and Farkas
et al each observed post-procedural HAE attacks despite
STP with C1 INH, our study found no attacks. Several
factors may contribute to this, including the sample size
in our study being smaller than in the others. In addition,
the doses of C1 INH used in our study (standard dose of
Table 1 Procedure breakdown
Procedure characteristics Patient characteristics
# Year Description C1 INH dose
Received (U)
Timing of C1 INH
administration
Gender Age Concomitant long–term
treatment for HAE
1 2013 Cesarian Section 2000 U Just prior to procedure Female 28 -
2 2013 Dental extraction 2000 U Just prior to procedure Male 49 -
3 2013 Vaginal child birth 1500 U Prior to delivery, while in
active labour
Female 26 -
4 2012 Inguinal hernia repair 1000 U/h × 3h For the length of the surgery
(3h)
Male 49 -
5 2012 Dental surgery 1500 U Just prior to procedure Female 62 -
6 2012 Port-o-cath placement 1500 U Just prior to procedure Female 27 -
7 2011 Port-o-cath placement 1500 U Just prior to procedure Female 26 -
8 2011 Hickman catheter placement 1500 U Just prior to procedure Female 25 -
9 2011 Vaginal child birth 1500 U Prior to delivery, while in
active labour
Female 33 -
10 2010 Dental extraction 1000 U Just prior to procedure Male 57 Danazol
11 2010 Dental extraction 1000 U Just prior to procedure Male 47 Danazol
12 2007 Dental surgery 1000 U Just prior to procedure Female 58 -
13 2006 Hernia repair 1000 U Just prior to procedure Female 46 -
14 2006 Dental extraction 1000 U Just prior to procedure Male 53 Danazol
15 2005 Dental extraction 1000 U Just prior to procedure Female 19 -
16 2004 Abdominal aneurysm repair 1500 U Just prior to procedure Male 51 Danazol
17 2003 Excision of melanoma-in-situ 1000 U Just prior to procedure Female 53 -
18 2003 Angiogram 1500 U Just prior to procedure Male 49 Danazol
19 2001 Liver biopsy 1500 U Just prior to procedure Male 38 Danazol
20 2000 Ascending and descending aortic
aneurysm repair
3000 U Just prior to procedure Male 47 Danazol
21 1998 Angiogram 1000 U Just prior to procedure Female 55 -
22 1998 Hysterectomy 1500 U Just prior to procedure Female 38 -
23 1997 Dental surgery 1000 U Just prior to procedure Female 39 -
24 1997 Aortic valve replacement 1500 U Just prior to procedure Male 44 Danazol
Table 2 Medications approved for the treatment of acute HAE attacks
Treatment of acute attacks
Medication class Example Dose Approval
Canada US Europe
C1 INH Replacement (plasma derived) Berinert 20 U/kg IV ✓ ✓ ✓
Cetor 1000 U IV ✓
Cinryze 1000 U IV ✓
Recombinant C1 INH Ruconest 50 U/kg IV ✓
Rhucin 50 U/kg IV Pending
Kallikrein Inhibitor Ecallantide 30 mg SC ✓
Bradykinin antagonist Icatibant 30 mg SC Pending ✓ ✓
Gavigan et al. Allergy, Asthma & Clinical Immunology 2014, 10:17 Page 3 of 5
http://www.aacijournal.com/content/10/1/17
Table 4 Medications approved for long-term prophylaxis
of HAE attacks
Long-term prophylaxis










Danazol ≦ 200 mg PO
TID
✓
Of note: androgens are contraindicated in: pregnancy, lactation, and growing
children. They are also associated with severe side-effects.
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IMPACT-1 trial in 2009) corresponded to a dose of 1000
U, 1500 U, or 2000 U for most patients. Thus, for 15/24
procedures, patients received doses greater than 1000 U,
which was greater than doses used by Grant et al (in 87/91
patients) and Bork et al. [6,7] and for all 24/24 procedures,
patients in our study received doses greater than the dose
of 500 U employed by Farkas et al. [8].
Historically, treatment options for HAE have included
stimulating endogenous C1 INH synthesis using attenu-
ated androgens, reducing C1 INH consumption with
protease inhibitors (e.g. transexamic acid), and replacing
C1 INH with fresh frozen plasma or C1 INH (plasma
derived or recombinant); plasma derived C1 INH being
the prefered option for acute attacks for the last 30 years
[9]. Recombinant C1 INH has also been investigated for
its use as a prophylactic treatment and prelimary results
may be promising; [10] however, the half-life for recom-
binant C1 INH is shorter than that of plasma derived,
which may limit its effectiveness for prophylaxis and
more data are needed before commencing this therapy.
Newer medications are approved for the treatment of
acute attacks, STP, or long-term prophylaxis. Tables 2, 3,
and 4, present the approved treatments in Canada, the
United States, and Europe for the treatement of acute
HAE attacks, short-term prophylaxis of HAE attacks,
and long-term prophylaxis of HAE attacks, respectively.
The 2010 International consensus algorithm for the
diagnosis, therapy and management of HAE provided
guidelines for STP, suggesting that it is not routinely re-
quired before minor manipulations (e.g. minor dental
work), so long as C1 INH is immediately available and the
manipulation has not previously triggered an attack. For
major procedures or intubation, they recommended short-
term prophylactic C1 INH 1-6 hours before the procedure
[11]. Similarly, the WAO urges considering prophylactic
C1 INH 1-6 hours before surgeries, especially dental andTable 3 Medications approved for short-term prophylaxis
of HAE attacks
Short-term prophylaxis




















Of note: androgens are contraindicated in: pregnancy, lactation, and growing
children. They are also associated with severe side-effects.
*Recommendation varies as dose yet to be fully investigated.intraoral, those requiring endotracheal intubation, those
manipulating the upper airway or pharynx, and for endos-
copy and bronchoscopy procedures [4]. Both groups ac-
knowledged that the optimal dose of C1 INH is unknown,
but suggest a dose of 10-20 U/kg [4,11], or 1000 U [4].
Finally, the US Hereditary Angioedema Association Medical
Advisory Board 2013 recommended that C1 INH for STP
be administered 1-12 hours before the stressor; alterna-
tively, anabolic steroids given 7-10 days before the stressor
may be provided for STP. The importance of having on-
demand treatment available, regardless of whether the pa-
tient was given STP for the stressor or not, was strongly
emphasized [12].
Conclusions
We have demonstrated successful use of C1 INH as STP
for Type I HAE patients undergoing invasive procedures.
Our study was limited by our small sample size, the retro-
spective design, and only assessing a single agent, C1 INH.
Other agents, such as attenuated androgens, fresh frozen
plasma, and transexamic acid were not specifically in-
cluded in our study. Although future prospective trials are
needed, data suggest that pre-procedural treatment with
C1 INH, Berinert®, may be an effective to substantially
decrease post-procedural HAE attacks.
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